REFERENCE PRICINIG PROPOSAL BASED ON GROSS DOMESTIC PRODUCT PER CAPITA

Daylan Koçkaya P., Wertheimer A.

ISPOR 17th Annual International Meeting, 2-6 June 2012, Washington, DC, USA, Washington, Amerika Birleşik Devletleri, 2 - 06 Haziran 2012, ss.21

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Washington
  • Basıldığı Ülke: Amerika Birleşik Devletleri
  • Sayfa Sayıları: ss.21
  • Kocaeli Üniversitesi Adresli: Evet

Özet

taken into account during reference piricing, these price are still relativley high

according to our country’s purchasing power. The price of a certain medication is

considered normal in a developed country whereas that price for the same product

presents itself higher than the purchasing power of developing country.Development

of a new reference pricing system estimated in accordance with Turkey’s

GDPC is proposed. METHODS: The most essential requirement for reference pricing

is to reach a new reference price based on the molecule significance coefficient-

(MSC) - obtained through an assessment and GDPC no higher than the lowest

reference country price. A committe of 5 academicians convened from different

universities has evaluated bevacizumab, erlotinib and rituximab, using the assessment

form prepared on grounds of 5 questions for the calculation of the coefficient.

New public pricesof the products were calculated by the use of the MSC. The pharmaceutical

product pricing calculation is suggested as below: Product Price  


(Country GDPC/Ref. Country GDPC Ref. Country Price) Molecule Significance

Coefficient; Mol. Sig. Coeff.  Average Score/Total Score 3. RESULTS: The MSC

values for bevacizumab, erlotinib and rituximab were 1.09, 1.21 and 1.29, respectively.

The probable the new calculated public prices depending the formulas were

decreased from the public price, 37%, 40% and 21%, respectively. CONCLUSIONS:

GDPC-based reference pricing sample may provide a new perspective in pharmaeutical

pricing control in countries like Turkey. On the other hand, this can also

provide an opinion for countries with insufficient facilities for approaching MSC

and HTA, during reimbursement decision making. For instance, an MSC value

under 1 is not included in reimbursement whereas one falling in between 2 and 3 is

suggested for reimbursement.This can be similarly used for determining the MSC

reimbursement levels independent from reference pricing.